vTv Therapeutics (NASDAQ:VTVT) Share Price Crosses Below 50 Day Moving Average – Time to Sell?

vTv Therapeutics Inc. (NASDAQ:VTVT)’s stock price crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $35.86 and traded as low as $32.90. vTv Therapeutics shares last traded at $33.72, with a volume of 46,095 shares traded.

Analysts Set New Price Targets

Several research analysts have recently issued reports on VTVT shares. BTIG Research reissued a “buy” rating and issued a $49.00 target price on shares of vTv Therapeutics in a research report on Wednesday, March 11th. Evercore initiated coverage on vTv Therapeutics in a research report on Thursday, March 12th. They issued an “outperform” rating and a $44.00 target price for the company. Zacks Research upgraded vTv Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. Wall Street Zen upgraded vTv Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings upgraded vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Monday, May 18th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $53.00.

vTv Therapeutics Stock Up 1.7%

The firm has a market capitalization of $132.86 million, a PE ratio of -36.26 and a beta of 0.26. The firm’s fifty day simple moving average is $35.86 and its 200-day simple moving average is $34.85.

vTv Therapeutics (NASDAQ:VTVT) last issued its earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $1.44. The firm had revenue of $36.84 million during the quarter, compared to analysts’ expectations of $20.00 million. As a group, analysts predict that vTv Therapeutics Inc. will post -2.19 earnings per share for the current year.

Institutional Trading of vTv Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of VTVT. Baker BROS. Advisors LP increased its holdings in shares of vTv Therapeutics by 52.4% in the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock worth $3,463,000 after purchasing an additional 51,000 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after purchasing an additional 12,896 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in shares of vTv Therapeutics in the 4th quarter worth $221,000. Finally, 683 Capital Management LLC bought a new stake in shares of vTv Therapeutics in the 4th quarter worth $731,000. Institutional investors own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.